Literature DB >> 2105452

Effects of testosterone and growth hormone treatment on hepatic microsomal P450 expression in the diabetic rat.

K E Thummel1, J B Schenkman.   

Abstract

The profile of hepatic microsomal cytochrome P450 expressed in the male and female rat was dramatically altered by streptozotocin-induced diabetes. In the diabetic male, P450 forms IIC11, IIC13, IIA2, and IIIA2 were suppressed and forms IIA1 and IIC12 were induced to the levels observed in the immature male rat. A 6- to 8-fold induction of P450 IIE1 was detected in both male and female diabetic rats. A member of the P450 IIIA family was also induced in the diabetic female rat. Accompanying the change in P450 profile in the diabetic male rat was reduction in circulating testosterone and tetraiodothyronine concentrations and a sharp diminution of the normally pulsatile pattern of growth hormone secretion. In contrast to the male rat, the growth hormone secretion pattern in the diabetic female rat was unchanged from control. The hormone and P450 profiles detected in the diabetic male rat suggest a reversion to an immature physiological state. Testosterone replacement treatments carried out for 2 weeks slightly but significantly affected the suppression of P450 IIC11 and reversed the changes in P450 IIA2, IIIA2, and IIC12 in the diabetic male, without altering the suppressed state of growth hormone secretion. However, 1 week of human growth hormone, administered intravenously every 4 hr to diabetic male rats, failed to significantly reverse the diabetes-induced changes in hepatic cytochromes P450, in particular forms IIC11 and IIE1, despite the presence of an episodic plasma hGH profile. An induction of P450 IIE1 in diabetic female rats, without a reduction in growth hormone secretion, suggests that its induction in diabetes in both sexes is not related to changes in growth hormone. In addition, the results of testosterone treatment on the expression of IIC12, IIA2, and IIIA2 in the diabetic male rat suggest a regulatory role for this hormone that does not involve the pituitary secretion of growth hormone. However, the lack of effect of human growth hormone treatment in the diabetic male on levels of individual P450 forms indicates that in diabetes there may be a change in the ability of the male rat hepatocyte to respond to a somatic signal, possibly as a result of the changes in other hormone factors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2105452

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  17 in total

1.  Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes.

Authors:  Dan Xu; Feng Li; Mian Zhang; Ji Zhang; Can Liu; Meng-yue Hu; Ze-yu Zhong; Ling-ling Jia; Da-wei Wang; Jie Wu; Li Liu; Xiao-dong Liu
Journal:  Acta Pharmacol Sin       Date:  2014-08-25       Impact factor: 6.150

Review 2.  Drug disposition in pathophysiological conditions.

Authors:  Adarsh Gandhi; Bhagavatula Moorthy; Romi Ghose
Journal:  Curr Drug Metab       Date:  2012-11       Impact factor: 3.731

3.  Sex steroid hormones regulate constitutive expression of Cyp2e1 in female mouse liver.

Authors:  Maria Konstandi; Jie Cheng; Frank J Gonzalez
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-04-02       Impact factor: 4.310

4.  Lack of effect of growth hormone replacement therapy on CYP1A2 and xanthine oxidase activities in growth hormone-deficient children.

Authors:  Esteban Mayayo-Sinués; Ana Fanlo; Blanca Sinués; Esteban Mayayo; Jose I Labarta; Angel García de Jalón; Angel Ferrández-Longás
Journal:  Eur J Clin Pharmacol       Date:  2006-01-12       Impact factor: 2.953

5.  Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus.

Authors:  Miroslav Dostalek; Michael H Court; Bingfang Yan; Fatemeh Akhlaghi
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

6.  Effect of CYP3A1(23) induction on clarithromycin pharmacokinetics in rats with diabetes mellitus.

Authors:  Yu C Kim; Joo H Lee; So H Kim; Myung G Lee
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

7.  Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic enzymes.

Authors:  Susumu Kodama; Chika Koike; Masahiko Negishi; Yukio Yamamoto
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

8.  Induction of the Cyp1a-1 dioxin-responsive enhancer in transgenic mice.

Authors:  S N Jones; P G Jones; H Ibarguen; C T Caskey; W J Craigen
Journal:  Nucleic Acids Res       Date:  1991-12-11       Impact factor: 16.971

Review 9.  Phosphorylation and protein-protein interactions in PXR-mediated CYP3A repression.

Authors:  Satyanarayana R Pondugula; Hanqing Dong; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-08       Impact factor: 4.481

10.  Effects of growth hormone deficiency and rhGH replacement therapy on the 6beta-hydroxycortisol/free cortisol ratio, a marker of CYP3A activity, in growth hormone-deficient children.

Authors:  Blanca Sinués; Esteban Mayayo; Ana Fanlo; Esteban Mayayo; María L Bernal; Pilar Bocos; Elena Bello; Jose I Labarta; Angel Ferrández-Longás
Journal:  Eur J Clin Pharmacol       Date:  2004-09-07       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.